Dermatite seborreica

Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015 Feb 1;91(3):185-90.Texto completo  Resumo

Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013 Sep 4;93(5):557-61.Texto completo  Resumo

Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Drugs Dermatol. 2013 Mar;12(3):312-5. Resumo

1. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015 Feb 1;91(3):185-90.Texto completo  Resumo

2. Friedmann DP, Mishra V, Batty T. Progressive facial papules in an African-American patient: an atypical presentation of seborrheic dermatitis. J Clin Aesthet Dermatol. 2018;11(7):44-45.Texto completo  Resumo

3. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology (Basel). 2004;208(2):89-93. Resumo

4. Foley P, Zuo Y, Plunkett A, et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003 Mar;139(3):318-22. Resumo

5. Mastrolonardo M, Diaferio A, Vendemiale G, et al. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol. 2004;84(4):285-7. Resumo

6. Kamamoto CSL, Nishikaku AS, Gompertz OF, et al.Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial. Dermatoendocrinol. 2017;9(1):e1361573.Texto completo  Resumo

7. Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

8. Faergemann J. Severe seborrheic dermatitis. J Int Postgrad Med. 1990;2:18-20.

9. Almutairi N, Schwartz RA. COVID-19 with dermatologic manifestations and implications: an unfolding conundrum. Dermatol Ther. 2020 Sep;33(5):e13544.Texto completo  Resumo

10. Rudd E, Walsh S. Mask related acne ("maskne") and other facial dermatoses. BMJ. 2021 Jun 7;373:n1304.Texto completo  Resumo

11. Tollesson A, Frithz A, Berg A, et al. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol. 1993 Jun;28(6):957-61. Resumo

12. Wikramanayake TC, Borda LJ, Miteva M, et al. Seborrheic dermatitis-Looking beyond Malassezia. Exp Dermatol. 2019 Sep;28(9):991-1001.Texto completo  Resumo

13. Scognamiglio P, Chiaradia G, De Carli G, et al. The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infect Dis. 2013 Oct 10;13:473.Texto completo  Resumo

14. Berk T, Scheinfeld N. Seborrheic dermatitis. P T. 2010 Jun;35(6):348-52.Texto completo  Resumo

15. Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrheic dermatitis. Br J Dermatol. 2011 Mar;164(3):652-6. Resumo

16. Lallas A, Argenziano G, Apalla Z, et al. Dermoscopic patterns of common facial inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2014 May;28(5):609-14. Resumo

17. John AM, Schwartz RA, Janniger CK. The kerion: an angry tinea capitis. Int J Dermatol. 2018 Jan;57(1):3-9. Resumo

18. Sanghvi SY, Schwartz RA. Leiner's disease (erythroderma desquamativum): a review and approach to therapy. Dermatol Ther. 2021 Jan;34(1):e14510. Resumo

19. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007 Aug;57(2):257-64. Resumo

20. Hebert AA. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Clin Ther. 2006 Dec;28(12):1972-82. Resumo

21. Firooz A, Solhpour A, Gorouhi F. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006 Aug;142(8):1066-7. Resumo

22. Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446.Texto completo  Resumo

23. Shuster S, Meynadier J, Kerl H, et al. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005 Jan;141(1):47-52. Resumo

24. Swinyer LJ, Decroix J, Langner, A. Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. Cutis. 2007 Jun;79(6):475-82. Resumo

25. Victoire A, Magin P, Coughlan J, et al. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Cochrane Database Syst Rev. 2019 Mar 4;3:CD011380.Texto completo  Resumo

26. Apasrawirote W, Udompataikul M, Rattanamongkolgul S. Topical antifungal agents for seborrheic dermatitis: systematic review and meta-analysis. J Med Assoc Thai. 2011 Jun;94(6):756-60. Resumo

27. Schwartz JR, Bacon RA, Shah R, et al. Therapeutic efficacy of anti-dandruff shampoos: a randomized clinical trial comparing products based on potentiated zinc pyrithione and zinc pyrithione/climbazole. Int J Cosmet Sci. 2013;35:2013 Aug;35(4):381-7. Resumo

28. Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014 Jun;25(3):226-31. Resumo

29. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermat. 2006 Jun;54(6):1083-8. Resumo

30. Pierard-Franchimont C, Pierard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204(4):344-7. Resumo

31. Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:2007 Oct;6(10):1001-8. Resumo

32. Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(1):25-9.Texto completo  Resumo

33. Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007 Mar;21(3):345-50. Resumo

34. Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20(6):344-9. Resumo

35. Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013 Sep 4;93(5):557-61.Texto completo  Resumo

36. Groisser D, Bottone EJ, Lebwohl M. Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1989 May;20(5 Pt 1):770-3. Resumo

37. Medicines and Healthcare Products Regulatory Agency. Oral ketoconazole: do not prescribe or use for fungal infections—risk of liver injury outweighs benefits. August 2013 [internet publication].Texto completo

38. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013 [internet publication].Texto completo

39. US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. July 2013 [internet publication].Texto completo

40. Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol. 2009 Aug;61(2):294-302. Resumo

41. Ang-Tiu CU, Medhrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: A systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012 Jan;5(1):91-7. Resumo

42. Ozden MG, Tekin NS, Ilter N, et al. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11(1):51-4. Resumo

43. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003 Jul;49(1):145-7. Resumo

44. Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Drugs Dermatol. 2013 Mar;12(3):312-5. Resumo

45. ClinicalTrials.gov. Safety and efficacy of ARQ-154 foam in subjects with seborrheic dermatitis. ClinicalTrials.gov Identifier: NCT04091646. Jul 2021 [internet publication].Texto completo

46. ClinicalTrials.gov. Trial of PDE4 inhibition with roflumilast for the management of seborrheic dermatitis (STRATUM). ClinicalTrials.gov Identifier: NCT04973228. Dec 2021 [internet publication].Texto completo